무세포 DNA 분리 및 추출 시장 - 세계 및 지역별 분석 : 제품별, 플랫폼별, 기술별, 용도별, 최종사용자별, 지역별 - 분석과 예측(2025-2035년)

Introduction to Cell-free DNA Isolation and Extraction Market

The use of cell-free DNA isolation and extraction kits, tubes, and other consumables has increased due to the rising prevalence of cancer, the increasing key player initiatives, and the rising government initiatives in the cell-free DNA isolation and extraction market. The constant significant investments by healthcare companies to meet industry demand and the growing adoption of cell-free DNA isolation and extraction kits, tubes, and reagents among major end users are the major factors propelling the growth of the global cell-free DNA isolation and extraction market.

Competitive Landscape

The global cell-free DNA isolation and extraction market comprise well-established and newly emerging companies. Several companies are attempting to sustain their position in the market by launching new products and raising funds to develop new products for the isolation and extraction of cell-free DNA from different sample types. Key market players of the global cell-free DNA isolation and extraction market witnessed product launch, product approval and business funding, and synergistic activities majorly during the period January 2021-March 2025. The inclination of companies toward product launches suggests that the companies are involved in continuously bringing new products to the market to isolate cell-free DNA, which is primarily attributed to an increase in liquid biopsy studies and approval of several liquid biopsy assays by the regulatory agencies.

Market Segmentation:

Market Segmentation:

Segmentation 1: by Product

• Cell-Free DNA Extraction and Isolation Kits
• Extraction and Isolation Tubes
• Other Consumables

Segmentation 2: by Platforms

• Polymerase Chain Reaction (PCR)
• Next-Generation Sequencing (NGS)
• Other

Segmentation 3: by Technique

• Magnetic Beads-Based
• Spin Column-Based
• Other

Segmentation 4: by Application

• Non-Invasive Prenatal Testing (NIPT)
• Oncology
• Transplant Rejection
• Other Applications

Segmentation 5: by End User

• Academic Research Institutes and Laboratories
• Pharmaceutical and Biotechnology Companies
• Clinical Diagnostic Centers
• Contract Research Organizations (CROs)
• Others (Forensic, Biobanks)

Segmentation 6: by Region

• North America
• Europe
• Asia-Pacific
• Latin America
• Rest-of-the-World

Key Questions Answered in the Report

• How is cell-free DNA isolation and extraction revolutionizing oncology?
• What are the major market drivers, challenges, and opportunities in the global cell-free DNA isolation and extraction market?
• What are the underlying structures resulting in the emerging trends within the global cell-free DNA isolation and extraction market?
• What are the key development strategies that the major players are implementing in order to sustain themselves in the competitive market?
• What are the key regulatory implications in developed and developing regions pertaining to the use of cell-free DNA isolation and extraction-targeted therapies?
• What are the potential entry barriers expected to be faced by the companies willing to enter a particular region?
• How is each market segment expected to grow during the forecast period 2025-2035, and what is the anticipated revenue to be generated by each segment? Following are the segments:
  • Product (Cell-Free DNA Extraction and Isolation Kits, Extraction and Isolation Tubes, Other Consumables)
  • Platform (Polymerase Chain Reaction (PCR), Next Generation Sequencing (NGS), and Other Platforms)
  • Technique (Magnetic Beads-Based, Spin Column-Based, and Other Techniques)
  • Application (Non-Invasive Prenatal Testing (NIPT), Oncology, Transplant Rejections, Other Applications)
  • End User (Pharmaceutical and Biotechnology Companies, Academic and Research Institutions, Contract Research Organizations (CROs), and Other End Users)
  • Region (North America, Europe, Asia-Pacific, Latin America, and Rest-of-the-World)
• What are the growth opportunities for the cell-free DNA isolation and extraction companies in the region of their operation?
• Who are the leading players with significant offerings in the global cell-free DNA isolation and extraction market?
• Which companies are anticipated to be highly disruptive in the future, and why?

Table of Contents

Executive Summary

Scope and Definition

Market/Product Definition

Inclusion and Exclusion

Key Questions Answered

Analysis and Forecast Note

1. Markets Overview

• 1.1 Market Definition
• 1.2 Early Discovery and Application of cfDNA
• 1.3 Properties of cfDNA
• 1.4 Biological Role of cfDNA
• 1.5 Extraction of Circulating cfDNA
• 1.6 Application of Circulating cfDNA
• 1.7 Market Footprint and Growth Potential
• 1.8 Interruption in Research and Clinical Development and Commercial Operation
  • 1.8.1 Research and Clinical Development
  • 1.8.2 Commercial Operation
  • 1.8.3 Navigating Crisis Recovery and Looking to the Future

2. Global Cell-Free DNA Isolation and Extraction Market: Industry Analysis

• 2.1 Overview
• 2.2 Legal Requirements and Framework in the U.S.
  • 2.2.1 FDA Regulation
• 2.4 Legal Requirements and Framework in Asia-Pacific
  • 2.4.1 China
  • 2.4.2 Japan

3. Market Dynamics

• 3.1 Overview
• 3.2 Impact Analysis
• 3.3 Market Drivers
• 3.4 Market Restraints
• 3.5 Market Opportunities

4. Competitive Landscape

• 4.1 Overview
• 4.2 Product Launch and Upgradations
• 4.3 Product Approvals and Business Funding
• 4.4 Synergistic Activities
• 4.5 Mergers and Acquisitions
• 4.6 Market Share Analysis (by Company), 2023 and 2024
• 4.7 Growth Share Analysis (by Company)

5. Global Cell-Free DNA Isolation and Extraction Market (by Product) $Million, 2023-2035

• 5.1 Overview
• 5.2 Cell-Free DNA Isolation and Extraction Kits
• 5.3 Cell-Free DNA Isolation and Extraction Tubes
• 5.4 Other Consumables

6. Global Cell-Free DNA Isolation and Extraction Market (by Platform), $Million, 2023-2035

• 6.1 Overview
• 6.2 Next-Generation Sequencing (NGS)
• 6.3 Polymerase Chain Reaction (PCR)
• 6.4 Real-Time Polymerase Chain Reaction (RT-PCR)
• 6.5 Digital Polymerase Chain Reaction (dPCR)
• 6.6 Other Platforms

7. Global Cell-Free DNA Isolation and Extraction Market (by Techniques), $Million, 2023-2035

• 7.1 Overview
• 7.2 Magnetic Beads-Based
• 7.3 Spin Column-Based
• 7.4 Other Techniques

8. Global Cell-Free DNA Isolation and Extraction Market (by Application), $Million, 2023-2035

• 8.1 Overview
• 8.2 Non-Invasive Prenatal Testing (NIPT)
• 8.3 Oncology
  • 8.3.1 Solid Tumor
  • 8.3.2 Hematological Malignancies
• 8.4 Transplant Rejection
• 8.5 Other Applications

9. Global Cell-Free DNA Isolation and Extraction Market (by End User), $ Million, 2023-2035

• 9.1 Overview
• 9.2 Pharmaceutical and Biotechnology Companies
• 9.3 Academic Research Institutes and Laboratories
• 9.4 Contract Research Organizations (CROs)
• 9.5 Clinical Diagnostic Centers
• 9.6 Other End Users

10. Global Cell-Free DNA Isolation and Extraction Market (by Region), $ Million, 2023-2035

• 10.1 Overview
• 10.2 North America
  • 10.2.1 U.S.
  • 10.2.2 Canada
• 10.3 Europe
  • 10.3.1 Germany
  • 10.3.2 France
  • 10.3.3 U.K.
  • 10.3.4 Italy
  • 10.3.5 Spain
  • 10.3.6 Denmark
  • 10.3.7 Rest-of-Europe
• 10.4 Asia-Pacific
  • 10.4.1 China
  • 10.4.2 India
  • 10.4.3 Japan
  • 10.4.4 South Korea
  • 10.4.5 Australia
  • 10.4.6 Singapore
  • 10.4.7 Rest-of-Asia-Pacific (RoAPAC)
• 10.5 Latin America
  • 10.5.1 Brazil
  • 10.5.2 Mexico
  • 10.5.3 Rest-of-Latin America (RoLA)
• 10.6 Rest-of-the-World

11. Company Profiles

• 11.1 Thermo Fisher Scientific Inc.
  • 11.1.1 Company Overview
  • 11.1.2 Product Portfolio
  • 11.1.3 Target Customers/End Users
  • 11.1.4 Analyst View
• 11.2 QIAGEN
  • 11.2.1 Company Overview
  • 11.2.2 Product Portfolio
  • 11.2.3 Target Customers/End Users
  • 11.2.4 Analyst View
• 11.3 Danaher Corporation
  • 11.3.1 Company Overview
  • 11.3.2 Product Portfolio
  • 11.3.3 Target Customers/End Users
  • 11.3.4 Analyst View
• 11.4 PerkinElmer, Inc.
  • 11.4.1 Company Overview
  • 11.4.2 Product Portfolio
  • 11.4.3 Target Customers/End Users
  • 11.4.4 Analyst View
• 11.5 Endress+Hauser AG
  • 11.5.1 Company Overview
  • 11.5.2 Product Portfolio
  • 11.5.3 Target Customers/End Users
  • 11.5.4 Analyst View
• 11.6 Agilent Technologies, Inc.
  • 11.6.1 Company Overview
  • 11.6.2 Product Portfolio
  • 11.6.3 Target Customers/End Users
  • 11.6.4 Analyst View
• 11.7 F. Hoffmann-La Roche Ltd.
  • 11.7.1 Company Overview
  • 11.7.2 Product Portfolio
  • 11.7.3 Target Customers/End Users
  • 11.7.4 Analyst View
• 11.8 Merck KGaA
  • 11.8.1 Company Overview
  • 11.8.2 Product Portfolio
  • 11.8.3 Target Customers/End Users
  • 11.8.4 Analyst View
• 11.9 llumina, Inc.
  • 11.9.1 Company Overview
  • 11.9.2 Product Portfolio
  • 11.9.3 Target Customers/End Users
  • 11.9.4 Analyst View
• 11.10 Takara Bio Inc.
  • 11.10.1 Company Overview
  • 11.10.2 Product Portfolio
  • 11.10.3 Target Customers/End Users
  • 11.10.4 Analyst View
• 11.11 Aline Biosciences
  • 11.11.1 Company Overview
  • 11.11.2 Product Portfolio
  • 11.11.3 Target Customers/End Users
  • 11.11.4 Analyst View
• 11.12 EpiGentek Group, Inc.
  • 11.12.1 Company Overview
  • 11.12.2 Product Portfolio
  • 11.12.3 Target Customers/End Users
  • 11.12.4 Analyst View
• 11.13 Omega Bio-tek, Inc.
  • 11.13.1 Company Overview
  • 11.13.2 Product Portfolio
  • 11.13.3 Target Customers/End Users
  • 11.13.4 Analyst View
• 11.14 Promega Corporation
  • 11.14.1 Company Overview
  • 11.14.2 Product Portfolio
  • 11.14.3 Target Customers/End Users
  • 11.14.4 Analyst View
• 11.15 Streck, Inc.
  • 11.15.1 Company Overview
  • 11.15.2 Product Portfolio
  • 11.15.3 Target Customers/End Users
  • 11.15.4 Analyst View
• 11.16 AccuBioMed Co., Ltd.
  • 11.16.1 Company Overview
  • 11.16.2 Product Portfolio
  • 11.16.3 Target Customers/End Users
  • 11.16.4 Analyst View
• 11.17 AMSBIO
  • 11.17.1 Company Overview
  • 11.17.2 Product Portfolio
  • 11.17.3 Target Customers/End Users
  • 11.17.4 Analyst View
• 11.18 Covaris, Inc.
  • 11.18.1 Company Overview
  • 11.18.2 Product Portfolio
  • 11.18.3 Target Customers/End Users
  • 11.18.4 Analyst View
• 11.19 EntroGen, Inc.
  • 11.19.1 Company Overview
  • 11.19.2 Product Portfolio
  • 11.19.3 Target Customers/End Users
  • 11.19.4 Analyst View
• 11.20 NeoGeneStar LLC
  • 11.20.1 Company Overview
  • 11.20.2 Product Portfolio
  • 11.20.3 Target Customers/End Users
  • 11.20.4 Analyst View
• 11.21 Norgen Biotek Corporation
  • 11.21.1 Company Overview
  • 11.21.2 Product Portfolio
  • 11.21.3 Target Customers/End Users
  • 11.21.4 Analyst View
• 11.22 STRATEC SE
  • 11.22.1 Company Overview
  • 11.22.2 Product Portfolio
  • 11.22.3 Target Customers/End Users
  • 11.22.4 Analyst View
• 11.23 System Biosciences, LLC
  • 11.23.1 Company Overview
  • 11.23.2 Product Portfolio
  • 11.23.3 Target Customers/End Users
  • 11.23.4 Analyst View

12. Research Methodology